BIGBEAR
PHARMACEUTICAL
Sotorasib covalently binds to the switch pocket of KRAS G12C mutant protein, specifically inhibits GTPase activity and blocks abnormal RAS signaling.
AuthenticGuaranteeFast DeliveryPrivacy For pregnant and lactating patients, if Sotorasib is to be used, it should be strictly in accordance with the doctor's advice, and do not use the ···【More】
Update: 03 Jul,2026Source: BigbearViews: 122
Sotorasib Daily PrecautionsWhat daily precautions should be taken during Sotorasib treatment? It is important to actively maintain contact with your d···【More】
Update: 03 Jul,2026Source: BigbearViews: 105
Mechanism of Action of SotorasibIrreversibly and selectively inhibits KRASG12C mutation, selectively inhibits KRAS signaling and cell growth in vitro,···【More】
Update: 03 Jul,2026Source: BigbearViews: 111
Sotorasib is the first approved KRAS G12C-targeted therapy, indicated for the treatment of non-small cell lung cancer and colorectal cancer with KRAS ···【More】
Update: 03 Jul,2026Source: BigbearViews: 99
Side Effects of SotorasibHematologicVery common (≥10%): lymphopenia (up to 48%), decreased hemoglobin (up to 43%), prolonged activated partial thrombo···【More】
Update: 03 Jul,2026Source: BigbearViews: 110
Use of Sotorasib may cause a range of side effects, some of which are serious and require prompt medical attention. During treatment with Sotorasib, c···【More】
Update: 02 Jul,2026Source: BigbearViews: 114
If adverse reactions occur, a maximum of 2 dose reductions are permitted: first dose reduction, 480 mg orally once daily; second dose reduction, 240 m···【More】
Update: 01 Jul,2026Source: BigbearViews: 121
Sotorasib is indicated for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at leas···【More】
Update: 30 Jun,2026Source: BigbearViews: 118
Sotorasib is an oral targeted cancer therapy drug that received U.S. FDA approval in May 2021 (marketed under the brand name Lumakras). It is indicate···【More】
Update: 27 Apr,2026Source: BigbearViews: 155
KRAS mutations have been considered a major challenge in cancer research, remaining difficult to overcome for many years. The introduction of Sotorasi···【More】
Update: 04 Mar,2026Source: BigbearViews: 137
Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021.I.···【More】
Update: 03 Mar,2026Source: BigbearViews: 143
In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib for the treatment of certain adult patients with non-sm···【More】
Update: 03 Mar,2026Source: BigbearViews: 145
Sotorasib is an oral targeted anticancer drug developed by Amgen, a small molecule inhibitor specifically targeting the KRAS G12C mutation.Indications···【More】
Update: 03 Mar,2026Source: BigbearViews: 147
Sotorasib is a targeted drug against KRASG12C mutations, primarily used to treat malignant tumors such as non-small cell lung cancer. Common side effe···【More】
Update: 27 Feb,2026Source: BigbearViews: 137
While taking sottorazib, it is generally not recommended to consume large amounts of fatty foods. However, small or occasional intake is usually harml···【More】
Update: 27 Feb,2026Source: BigbearViews: 129
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
